The Relapsing Multiple Sclerosis (RMS) drugs in development market research report provides comprehensive information on the therapeutics under development for Relapsing Multiple Sclerosis (RMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Relapsing Multiple Sclerosis (RMS). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Relapsing Multiple Sclerosis (RMS) and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Relapsing Multiple Sclerosis (RMS) by 11 companies/universities/institutes. The top development phase for Relapsing Multiple Sclerosis (RMS) is phase iii with eight drugs in that stage. The Relapsing Multiple Sclerosis (RMS) pipeline has 17 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Relapsing Multiple Sclerosis (RMS) pipeline products market are: Sanofi, Novartis and Genentech USA.
The key targets in the Relapsing Multiple Sclerosis (RMS) pipeline products market include Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2), B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1), and CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG).
The key mechanisms of action in the Relapsing Multiple Sclerosis (RMS) pipeline product include Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Inhibitor with four drugs in Phase III. The Relapsing Multiple Sclerosis (RMS) pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Relapsing Multiple Sclerosis (RMS) pipeline products market including Small Molecule, and Monoclonal Antibody.
Relapsing Multiple Sclerosis (RMS) overview
Multiple sclerosis (MS) is the most common disabling neurological disease of young adults with symptom onset generally occurring between the ages of 20 to 40 years. In MS, the immune system cells that normally protect us from viruses, bacteria, and unhealthy cells mistakenly attack myelin in the central nervous system (brain, optic nerves, and spinal cord). Myelin is a substance that makes up the protective sheath (myelin sheath) that coats nerve fibers (axons). Eventually, the disease can cause permanent damage or deterioration of the nerve fibers.
For a complete picture of Relapsing Multiple Sclerosis (RMS)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
